Pay in 4 interest-free payments of $6.66 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Consult a qualified medical provider before beginning any peptide therapy protocol
In the realm of cell-based therapies and antibodydrug conjugates (ADCs), CT041, a CLDN18.2-targeted CAR-T product, is being studied in gastrointestinal cancers (NCT04404595), while enfortumab vedotin, targeting Nectin-4, is under investigation for metastatic castration-resistant prostate cancer (NCT04754191)
Modified oxygen metabolism toward sunlight-friendly photodynamic therapy
Services, prices and nutrients may vary per location
/assets/images/provider/photos/2680950.jpg)
Right, volcano plot showing relative fold change (log 2 ) in ER-metabolite abundance versus log 10 (P value) from KPK cells expressing a sgRNA targeting intergenic region or sgRNA targeting Slc33a1
